Geoepidemiology of systemic sclerosis
Introduction
Systemic sclerosis (SSc) is a connective-tissue disease characterized by excessive collagen deposition in the dermis and internal organs and by vascular hyper-reactivity and obliterative microvascular phenomena. Patients with SSc are usually classified into two main groups, according to the extent of skin involvement: limited SSc (lSSc), with skin involvement essentially limited to the hands and face; and diffuse SSc (dSSc), with skin involvement proximal to the elbows and knees. In patients with lSSc, visceral involvement is rare, with the exception of patients in whom pulmonary arterial hypertension, interstitial lung disease and/or bowel involvement eventually develops. Patients with dSSc experience visceral involvement, including renal crisis, interstitial lung disease, pulmonary arterial hypertension, heart and gastrointestinal tract involvement.
The study of SSc represents a challenge for epidemiologists, because of the disease's rarity and the large spectrum of clinical manifestations and severity, with various diagnosis and classification criteria over time. Researchers have thus encountered many difficulties to carry out reliable surveys, since the disease is too rare to be detected by cross sectional population surveys. Therefore, epidemiologic studies of SSc are characterized by a particularly large variability in estimates of prevalence, incidence, risk factors and mortality rates, partly due to variability in the design and methods used to calculate these parameters. However, identifying changes in the epidemiological pattern of the disease may help in finding key determinants of risk and causal factors.
The absence of common definition criteria for SSc made epidemiologic studies very difficult to compare until the eighties. Therefore, prevalence and incidence estimates from the earlier surveys must be interpreted cautiously. In 1980, the American Rheumatism Association (ARA) classification, that was developed to distinguish SSc from other connective-tissue diseases, has provided a common definition of the disease [1], allowing more homogeneous epidemiological studies. Because it was designed for research applications and not for clinical diagnosis, it has been criticized for its low sensitivity in identifying early disease and milder forms of systemic scleroderma such as CREST syndrome. The name CREST is an acronym for the cardinal clinical features of the syndrome (calcinosis, Raynaud's phenomenon (RP), esophageal dysmotility, sclerodactyly, and telangiectasia). Thus, many authors also included patients with CREST features in their surveys. In 1988, LeRoy and colleagues proposed a new classification, splitting the disease's spectrum into two main forms: lSSc and dSSc. Finally, in 2001, Leroy and Medsger proposed revised criteria, including recent technological improvement, such as autoantibodies (anticentromere, topoisomerase, fibrillarin, PM-Scl, RNA polymerases I and III) and nailfold capillaroscopy for the diagnosis of early SSc [2] that distinguishes lSSc, with no detectable skin involvement; limited cutaneous SSc (lcSSc), with skin involvement essentially limited to the hands and face and diffuse cutaneous SSc (dcSSc), with skin involvement proximal to the elbows and knees. This classification is now used by most epidemiological studies of SSc, although some patients with dermatomyositis or mixed connective-tissue diseases might fulfil these criteria. Some authors also include “scleroderma spectrum disorders” encompassing dSSc and lSSc, CREST syndrome, SSc sine scleroderma, undifferentiated connective-tissue diseases (UCTD) and overlap syndromes. The resulting surveys hence provide higher prevalence/incidence estimates.
The method of case ascertainment differs widely among studies. Early studies usually used a single source of information. One of the most frequent methods was to review discharge diagnosis of SSc in major hospitals, using international disease classification codes, assuming that all patients were hospitalized because SSc is a severe disease. Such studies neglected outpatients that were not hospitalized and therefore underestimated the prevalence of the disease, especially for mild forms. Chandran et al. estimated that the inpatients-to-outpatients ratio was 1/1 in 3 hospitals of South Australia [3]. If this estimation is correct, the true prevalence of SSc is twofold the prevalence estimated by hospital based surveys. Moreover, single case ascertainment, including population-based administrative data (physician billing) and hospitalization databases do not have a sufficient sensitivity to provide reliable estimates of incidence/prevalence for SSc on their own [4]. Nowadays, most studies use multiple sources of ascertainment. This methodological improvement has been facilitated by the creation of computerized databases (ex: SASR in South Australia in 1993), patients support groups and access to public health insurance databases. In addition, statistical methods are now commonly employed, that take into account the incomplete case finding arising from a single source of ascertainment and correct the calculated prevalence rate. The most widely used is the so-called method of capture–recapture [5], [6], [7], that takes advantage of duplicate information derived from multiple sources of case ascertainment, to evaluate the degree of overlap among sources, estimate the number of cases missed by one source and hence estimate the true number of cases in a given area. On the opposite, all methods may overestimate the prevalence of the disease because of incorrect diagnoses of SSc in databases (for example, patients with mixed connective-tissue disease (MCTD) are often incorrectly encoded as SSc). Ideally, diagnoses should be confirmed by manual consultation of medical charts, but this is usually not possible for all cases. A good alternative is to estimate the proportion of reliable diagnoses using the available medical charts, and correct the number of the remaining unchecked cases accordingly [7].
Section snippets
Prevalence according to regions (Table 1)
Prevalence of SSc varies greatly according to the studies: from 7/million to 700/million inhabitants, when excluding specific clustering (see below). Large discrepancies exist among regions, and some of them may be the consequence of methodological variations only. However, SSc seems to be consistently more frequent in USA and Australia as compared to Europe and Japan.
Ethnicity
Several studies in USA have shown that black subjects have a higher age-specific incidence rate and more severe disease than white subjects [5], [6], [22], [24]. For example, in the study by Mayes et al. conducted in the region of Detroit, USA, SSc incidence was 31/million/year in black women versus 27/million/year in white women. Diffuse forms accounted for 60% versus 27% of the cases in black versus white SSc women [6]. Noteworthy, no difference in incidence according to race was noted for
According to time
Steen and Medsger [35] have demonstrated in the Pittsburg cohort that the ten-year cumulative survival has improved significantly from 54% in the 1970s to 66% in the 1990s (p < 0.001). Another large cohort in Italy showed the same trend, with a 10-year survival of 61% before 1985 versus 77% in more recent years [25]. Indeed, improved 10-year survival rates are reported in recent studies (73% in [36], 82% in [26]) compared with earlier ones [37]. Survival might be artificially prolonged by the
Take-home messages
- •
Prevalence of SSc is estimated between 3 and 24 per 100,000 population and appears to be higher in North America and Australia as compared to Europe and Japan.
- •
SSc occurs more frequently in female and black individuals.
- •
Reports of sporadic clusters of higher prevalence suggest the existence of environmental risk factors, but only silica and solvents exposure have been consistently associated with SSc.
- •
The ten-year cumulative survival has improved significantly from 54% in the 1970s to over 70% in
References (40)
- et al.
Incidence and prevalence of systemic sclerosis: a systematic literature review
Semin Arthritis Rheum
(2008) - et al.
Mortality in systemic sclerosis: an international meta-analysis of individual patient data
Am J Med
(2005) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee
Arthritis Rheum
(1980)- et al.
Criteria for the classification of early systemic sclerosis
J Rheumatol
(2001) - et al.
A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy
Aust NZ J Med
(1995) - et al.
Scleroderma prevalence: demographic variations in a population-based sample
Arthritis Rheum
(2009) - et al.
Racial differences in scleroderma among women in Michigan
Arthritis Rheum
(1997) - et al.
Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population
Arthritis Rheum
(2003) - et al.
Prevalence of systemic sclerosis in a French multi-ethnic county
Rheumatology (Oxford)
(2004) - et al.
Systemic sclerosis prevalence and comorbidities in the US, 2001–2002
Curr Med Res Opin
(2008)
Prevalence of scleroderma spectrum disorders in the general population of South Carolina
Arthritis Rheum
Scleroderma in South Australia: epidemiological observations of possible pathogenic significance
Intern Med J
Systemic sclerosis prevalence and mortality in Sydney 1974–88
Aust NZ J Med
Epidemiological study of patients with systemic sclerosis in Tokyo
Arch Dermatol Res
An epidemiological study of scleroderma in the West Midlands
Br J Rheumatol
Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants
Clin Exp Rheumatol
Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study
Medicine (Baltimore)
Geographical clustering of scleroderma in a rural area in the province of Rome
Clin Exp Rheumatol
Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype
Arthritis Rheum
Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis
J Rheumatol
Cited by (163)
Global, regional, and national incidence and prevalence of systemic sclerosis
2023, Clinical ImmunologyPulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis
2023, Heart Failure ClinicsScleroderma and interstitial lung disease - A case report
2022, Annals of Medicine and SurgeryIncidence and prevalence of systemic sclerosis in Sweden, 2004–2015, a register-based study
2022, Seminars in Arthritis and RheumatismCitation Excerpt :Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by the pathological triad of autoimmunity, endothelial dysfunction, and progressive fibrosis in multiple organs [1,2]. Because of its rarity and heterogeneous clinical presentation, the reliability and precision of reported incidence and prevalence estimates throughout the literature has varied greatly [3]. Variations among studies may partially be attributed to methodological differences with respect to study design, geographic region, and how the diagnosis of SSc was ascertained [3].
Pulmonary Hypertension Associated with Connective Tissue Disease
2022, Cardiology Clinics